Surviving sepsis--practice guidelines, marketing campaigns, and Eli Lilly.
Eichacker
Peter Q
PQ
Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
Natanson
Charles
C
Danner
Robert L
RL
D002986:Clinical Trials as Topic; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics; D006801:Humans; D040541:Marketing; D017410:Practice Guidelines as Topic; D011486:Protein C / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012109:Research Support as Topic; D018805:Sepsis / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration
D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated